Durability of the First Biologic in Children and Adults With Ulcerative Colitis: A Nationwide Study from the epi-IIRN.

Ohad AtiaChagit FrissGili FochtRamit Magen RimonNatan LeddermanShira GreenfeldAmir Ben-TovYiska Loewenberg WeisbandEran MatzYuri GorelikYehuda ChowersIris DotanDan Turner

Published in: Inflammatory bowel diseases (2024)

After 5 years of treatment, 43% of the patients with UC sustained their first biologic, with similar durability in pediatric and adult-onset onset disease. Anti-TNFs had similar durability to vedolizumab and superior durability when prescribed as combotherapy.

Keyphrases

ulcerative colitis
rheumatoid arthritis
patients with inflammatory bowel disease
replacement therapy
smoking cessation